MARKET

MNKD

MNKD

Mannkind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.060
+0.050
+1.66%
After Hours: 3.050 -0.01 -0.33% 18:39 05/16 EDT
OPEN
2.990
PREV CLOSE
3.010
HIGH
3.225
LOW
2.960
VOLUME
4.74M
TURNOVER
0
52 WEEK HIGH
5.53
52 WEEK LOW
2.490
MARKET CAP
772.85M
P/E (TTM)
-8.1557
1D
5D
1M
3M
1Y
5Y
MannKind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseas...
GlobeNewswire · 05/09 10:00
BRIEF-MannKind Corp Reports 2022 First Quarter Financial Results
reuters.com · 05/05 21:48
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:25
MannKind GAAP EPS of -$0.10 in-line, revenue of $11.99M beats by $1.38M
MannKind press release (NASDAQ:MNKD): Q1 GAAP EPS of -$0.10 in-line. Revenue of $11.99M (-31.3% Y/Y) beats by $1.38M. 1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 2021
Seekingalpha · 05/05 20:03
MannKind Q1 EPS $(0.10), Inline, Sales $11.99M Beat $10.58M Estimate
MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 100 percent decrease over losses of $(0.05) per share from the same period last year. The company
Benzinga · 05/05 20:01
-- Earnings Flash (MNKD) MANNKIND Posts Q1 Revenue $12M, vs. Street Est of $10.6M
MT Newswires · 05/05 16:04
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:15
MannKind Earnings Preview
MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that MannKind will report an earnings per share (EPS) of $-0.10.
Benzinga · 05/04 17:03
More
No Data
Learn about the latest financial forecast of MNKD. Analyze the recent business situations of Mannkind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
33.33%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MNKD stock price target is 6.00 with a high estimate of 8.00 and a low estimate of 5.00.
High8.00
Average6.00
Low5.00
Current 3.060
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 254
Institutional Holdings: 115.43M
% Owned: 45.70%
Shares Outstanding: 252.57M
TypeInstitutionsShares
Increased
51
7.54M
New
37
2.04M
Decreased
52
4.80M
Sold Out
23
1.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
James Shannon
Chief Executive Officer/Director
Michael Castagna
Chief Financial Officer
Steven Binder
Chief Human Resource Officer
Stuart Tross
Executive Vice President/General Counsel/Secretary
David Thomson
Executive Vice President
Alejandro Galindo
Chief Technology Officer
Joseph Kocinsky
Independent Director
Ronald Consiglio
Independent Director
Michael Friedman
Independent Director
Jennifer Grancio
Independent Director
Anthony Hooper
Independent Director
Sabrina Kay
Independent Director
Kent Kresa
Independent Director
Christine Mundkur
No Data
No Data
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

Webull offers kinds of MannKind Corporation stock information, including NASDAQ:MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.